Pisano Carmela, Cecere Sabrina Chiara, Di Napoli Marilena, Cavaliere Carla, Tambaro Rosa, Facchini Gaetano, Scaffa Cono, Losito Simona, Pizzolorusso Antonio, Pignata Sandro
Department of Urology and Gynecology, National Cancer Institute, 80131 Naples, Italy.
J Drug Deliv. 2013;2013:898146. doi: 10.1155/2013/898146. Epub 2013 Mar 14.
Among the pharmaceutical options available for treatment of ovarian cancer, increasing attention has been progressively focused on pegylated liposomal doxorubicin (PLD), whose unique formulation prolongs the persistence of the drug in the circulation and potentiates intratumor accumulation. Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. In 1999 it was first approved for platinum-refractory ovarian cancer and then received full approval for platinum-sensitive recurrent disease in 2005. PLD remains an important therapeutic tool in the management of recurrent ovarian cancer in 2012. Recent interest in PLD/carboplatin combination therapy has been the object of phase III trials in platinum-sensitive and chemonaïve ovarian cancer patients reporting response rates, progressive-free survival, and overall survival similar to other platinum-based combinations, but with a more favorable toxicity profile and convenient dosing schedule. This paper summarizes data clarifying the role of pegylated liposomal doxorubicin (PLD) in ovarian cancer, as well as researches focusing on adding novel targeted drugs to this cytotoxic agent.
在可用于治疗卵巢癌的药物中，聚乙二醇化脂质体阿霉素（PLD）越来越受到关注，其独特的制剂可延长药物在循环系统中的存留时间并增强肿瘤内蓄积。聚乙二醇化脂质体阿霉素（PLD）已成为上皮性卵巢癌常规治疗的主要组成部分。1999年它首次被批准用于铂类难治性卵巢癌，2005年又获得了对铂类敏感复发性疾病的全面批准。到2012年，PLD仍然是复发性卵巢癌治疗中的重要工具。最近对PLD/卡铂联合治疗的关注成为铂类敏感且未接受过化疗的卵巢癌患者III期试验的对象，试验报告其有效率、无进展生存期和总生存期与其他铂类联合方案相似，但毒性特征更有利且给药方案更便捷。本文总结了阐明聚乙二醇化脂质体阿霉素（PLD）在卵巢癌中作用的数据，以及专注于在这种细胞毒性药物中添加新型靶向药物的研究。
